REGENXBIO Inc.

AAV gene-therapy company advancing late-stage programs in Duchenne muscular dystrophy, retinal disease and rare genetic disorders.

Back to company catalog

Neuromuscular, retinal & rare genetic disease · AAV gene therapy · Pivotal / BLA planned Q3 2026

Compare report options